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Abstract Studies of non-steroidal anti-inflammatory drugs
(NSAIDs) in rheumatoid arthritis imply that inflammation
is important in the development of Alzheimer’s disease
(AD). However, these drugs have not alleviated the
symptoms of AD in those who have already developed
dementia. This suggests that the primary mediator targeted
by these drugs, PGE2, is not actively suppressing memory
function in AD. Amyloid-β oligomers appear to be
important for the mild cognitive changes seen in AD
transgenic mice, yet amyloid immunotherapy has also
proven unsuccessful in clinical trials. Collectively, these
findings indicate that NSAIDs may target a prodromal
process in mice that has already passed in those diagnosed
with AD, and that synaptic and neuronal loss are key
determinants of cognitive dysfunction in AD. While the
role of inflammation has not yet become clear, inflamma-
tory processes definitely have a negative impact on
cognitive function during episodes of delirium during
dementia. Delirium is an acute and profound impairment
of cognitive function frequently occurring in aged and
demented patients exposed to systemic inflammatory
insults, which is now recognised to contribute to long-
term cognitive decline. Recent work in animal models is
beginning to shed light on the interactions between
systemic inflammation and CNS pathology in these acute
exacerbations of dementia. This review will assess the role
of prostaglandin synthesis in the memory impairments
observed in dementia and delirium and will examine the
relative contribution of amyloid, synaptic and neuronal loss.
We will also discuss how understanding the role of inflam-
matory mediators in delirious episodes will have major
implications for ameliorating the rate of decline in the
demented population.
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Introduction
There is a long-running debate in Alzheimer’s disease (AD)
research as to why long-term treatment with non-steroidal
anti-inflammatory drugs (NSAIDs) very significantly pro-
tects against the subsequent development of AD but
treatment of AD patients with NSAIDs offers no relief for
those already experiencing the devastating memory loss
associated with this disease. This review takes as its starting
point the position that if NSAIDs offer no relief to patients
with AD then it is reasonable to conclude that the observed
memory dysfunction is not attributable to a direct inhibition
of memory processes by prostaglandins, the primary target
of these drugs. If NSAID dosing is appropriate to reduce
prostaglandin levels, but does not ameliorate memory
function then it is unlikely that prostaglandins are actively
interfering with memory in these patients. This, of course,
does not rule out the possibility that long-term exposure to
prostaglandins may influence the deposition or clearance of
amyloid-β (Aβ) or may result in significant damage, the
accumulation of which may impair memory function.
However, it appears that reducing prostaglandins in the
short term is not helpful. This appears contradictory to
multiple pre-clinical studies in which NSAIDs protected
against cognitive impairments in AD transgenic mice that
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tween cyclooxygenase (COX) activity and memory func-
tion. In addition, there is clear evidence from the
neuroinflammation field that prostaglandins can directly
impair memory function. Why, then, have these treatments
failed to offer any protection in AD patients? In this review
we attempt to examine the roles of COX and PGE2 in
memory function, both physiologically and pathologically,
and address the very substantial contribution neuronal
and synaptic loss makes to the burden of memory deficits
in AD.
Interogating the key determinants
of cognitive dysfunction in AD
Figure 1 shows a simple scheme summarising the major
proposed contributors to cognitive dysfunction in AD and in
the proceeding section we will attempt to look at the likely
contribution of each of these facets of pathology to cognitive
dysfunction in AD, based onwhat animal modelshave shown
us. It is clear that progressing disease, in humans with AD,
induces robust synaptic and neuronal loss, both of which
wouldbepredictedtoinducecognitivedeficits.Aβdeposition
and inflammation are also features of disease and there is
evidence that each of these factors can induce cognitive
deficits. The majority of research in elucidating the molecular
mechanisms of memory impairment in AD has come from
transgenic mouse models. The hallmark cognitive deficit of
patients with AD is a failure of episodic memory and though
recent studies have now made innovative efforts at examining
this in rats (Iordanova et al. 2009) and have described similar
‘episodic-like’ memory deficits in Tg2576 mice (Good and
Hale 2007), there have not yet been any mechanistic studies
addressing molecular mechanisms of such deficits. However,
a number of different cognitive tasks with some validity for
AD have been assessed in mice and it is interesting to
examine these with respect to the four possible pathological
culprits in Fig. 1.
Working memory
Working memory deficits in T-maze alternation tasks are the
mostfrequentlyreporteddeficitintheTg2576mouse(Stewart
etal. 2011) and are present in most widely used Aβ-inducing
transgenics (Chapman et al. 1999;C o r c o r a ne ta l . 2002;
Barnes et al. 2004; Caccamo et al. 2007; Cacucci et al. 2008;
Frye and Walf 2008; Filali and Lalonde 2009). These models
have all been described to show marked amyloidosis and
although there is some evidence of neuronal and synaptic
loss and disassembly, it has been striking how limited
neuronal pathology is in these models compared to that
observed in human AD (Wirths and Bayer 2010). This
indicates that the presence of Aβ peptides is sufficient to
produce working memory dysfunction in the absence of
neuronal or synaptic loss. This must be clearly distinguished
from synaptic dysfunction, for which there is robust
evidence. There is a very substantial literature on glutamate
receptor alterations and electrophysiological disruption and
caused by oligomeric species of Aβ (Shankar and Walsh
2009) but this is beyond the scope of the current review.
Despite any non-reliance of these T-maze deficits on synaptic
loss in the models so far studied, robust synaptic loss in the
CA1 of the hippocampus is sufficient, of itself, to produce
similar working memory deficits, as we have shown in the
Fig. 1 Potential contributors to cognitive dysfunction in Alzheimer’s
disease. It is known from experimental psychology and neuropathol-
ogy studies that neuronal and synaptic loss in the cortices and
hippocampus (both of which are prominent in AD) induce cognitive
impairments. The generation of amyloid plaques and of oligomeric
Aβ species occurs progressively during AD and there is clear
evidence that at least the latter contribute to cognitive impairments
seen in AD transgenic mice. Though linked by arrows, it is not proven
that synaptic loss and neuronal loss are caused by amyloidosis.
Microgliosis is apparent in AD and in transgenic models. Though
microglia surround plaques in transgenic models, microgliosis is also
an inevitable consequence of neuronal death and thus may be different
in models and in human AD. Neuroinflammation is widely described
as inducing cognitive deficits but it is difficult to extricate this from
direct effects of amyloid in animal models, and whether microglia
produce cognitively significant levels of prostaglandins remains
unclear despite the many NSAID studies of AD transgenics. Thus
early stage cognitive deficits in AD transgenics, and perhaps in AD
patients, maybe caused by Aβ with or without some contribution from
inflammatory responses
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Cunningham et al. 2003). Importantly, this synaptic loss
precedes neuronal loss (Cunningham et al. 2003)s ow ec a n
separate the contribution of these two elements of degener-
ation. Of course, neuronal loss in the same structure also
produces these deficits, as shown in several hippocampal
ablation studies (Bannerman et al. 1999, 2002). However,
CNSinflammatorymediatorproduction,inducedby200μg/kg
LPS intraperitoneally, fails to produce any deficit on this task
(Murray et al. 2010) and there are no demonstrations, to our
knowledge of non-neurotoxic doses of inflammogens impair-
ing T-maze alternation.
Visuospatial reference memory
We can pursue a similar line of enquiry with respect to
visuospatial reference memory deficits in the Morris Water
Maze (MWM). This is the most commonly assessed form
of memory in AD transgenics and deficits have consistently
been reported in this task. However, these deficits vary in
magnitude and time of onset, vary according to background
strain (Glazner et al. 2010) and have not been reported by
all laboratories (King and Arendash 2002). A recent meta-
analysis of multiple studies with Tg2576 reported that when
performance of control animals expressing human APP
without the Swedish mutation is taken into account, this
effect only becomes apparent between 12 and 18 months
and requires large numbers of animals (Reed et al. 2010). It
is also important to point out that AD transgenic mice can
actually learn this MWM task: they simply learn it more
slowly than wild-type controls (Kotilinek et al. 2002).
Performance in the MWM is well known to require intact
hippocampal function (Morris et al. 1982) and thus synaptic
and neuronal loss in the hippocampus obviously impair its
function. The question of whether inflammation can also
affect performance of this task is more complicated.
Multiple studies have reported deficits in this task after
administration of LPS or IL-1β while others have not noted
deficits (Cunningham and Sanderson 2008). However, the
task is ill-suited to assessment of cognition in animals that
are experiencing the reduced motivation, elevated stress
and anxiety, and compromised locomotor function that are
features of the sickness response. Measures of latency,
distance travelled to find the hidden platform, analysis of
route taken and appropriate probe trials must all be
examined to correctly distinguish cognitive impairments
from emotional and performance deficits that may appear as
cognitive deficits, as has been reviewed in detail elsewhere
(Cunningham and Sanderson 2008). Careful analysis of
these data suggests that inflammatory stimulation does not
robustly produce cognitive deficits on this visuospatial
reference task. This is an important point because these
studies of inflammation and MWM performance, coupled
with the impact of NSAIDs in AD transgenics, are usually
cited as key evidence that products of inflammation may
explain the deficits observed in AD. Neuroinflammation
produced by the intracerebroventricular infusion of
LPS can induce lasting cognitive deficits in the MWM
(Hauss-Wegrzyniak et al. 1998) However this inflammation
is more severe than that observed in transgenic models of
AD and since this chronic LPS treatment also induces death
of CA3 pyramidal neurons it is difficult to separate the
cognitive effects of neuroinflammation and cognitive effects
ofneuronaldeath.Nonetheless,herearenumerousreportsthat
anti-inflammatory treatments ameliorate cognitive dysfunc-
tion in AD transgenics so it is necessary to address whether
these drugs have successfully targeted inflammatory media-
tors or have affected other targets.
NSAIDs in AD transgenic mice
The evidence that prostaglandins do have some deleterious
effects in learning and memory is relatively clear: direct
application of PGE2 to the brain results in working memory
deficits in a runway task (Matsumoto et al. 2004) and has
also been shown to impair contextual fear-conditioning
(Hein et al. 2007). Furthermore there is evidence that COX-
2-overexpression can impair neuronal function. Aged
animals over-expressing neuronal COX-2 display behav-
ioural deficits and neuronal loss (Andreasson et al. 2001)
and female AD double transgenics over-expressing COX-2
have behavioural deficits that are abrogated by COX
inhibition (Melnikova et al. 2006), although the sex-
specificity of the latter findings makes them less compel-
ling. Thus, PGE2, the major target of NSAIDs, can impair
memory function but are prostaglandins key players in the
memory deficits seen in AD transgenics and in AD
patients? In a number of models of AD, NSAIDs have
been applied with beneficial effects. A number of studies
have shown amelioration of cognitive deficits in AD
transgenic mice after long-term treatment (months) with
flurbiprofen (Kukar et al. 2007), ibuprofen (Lim et al.
2001; Kotilinek et al. 2008), naproxen and MF-tricyclic
(Kotilinek et al. 2008), and COX-1-specific trifusal (Coma
et al. 2010). Long-term treatment with ibuprofen or, to a
lesser degree, indomethacin and other COX-1/2 inhibitors
can also reduce Aβ plaque load, Aβ1-42 levels or Aβ
42:40 ratios in the hippocampus and cortex (Lim et al.
2000; Yan et al. 2003; Heneka et al. 2005; Morihara et al.
2005; Kukar et al. 2007; McKee et al. 2008; Coma et al.
2010). Most of these drugs show some selectivity towards
COX-1. However, the relationship between COX inhibi-
tion, prostaglandin reduction and cognitive improvement
has not been carefully examined within these studies.
Morihara et al. (2005) suggested that ibuprofen, via effects
on IL-1 expression, decreased antichymotrypsin levels, thus
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(2004), also showed decreased NFκB activation/IL-1β
expression. In those studies where PGE2 was assessed it
appears that NSAID treatment does generally decrease
prostaglandin levels, but that neither PGE2 nor the enzymes
COX-1 and COX-2 showed significant disease-related
elevation in the transgenic mouse models used (Quinn
et al. 2003;S u n ge ta l . 2004; Kotilinek et al. 2008). Where
levels have been examined, those inhibitors with preferen-
tial inhibition of COX-1 have decreased PGE2 levels more
effectively than COX-2 selective inhibitors (Sung et al.
2004). No studies, to our knowledge have shown that PGE2
is elevated in AD transgenics and is reduced by treatment
with COX inhibitors, with a resulting improvement in
cognitive function. Therefore, a straightforward relationship
between PGE2 production and memory impairment cannot
be deduced from these studies despite the propensity of
COX inhibition to ameliorate these deficits.
It is also clear that there are ‘off-target’ effects of
NSAIDs, affecting relevant inflammatory and amyloido-
genic pathways. We mention some of these possibilities
here for completeness but comprehensive discussion of
these topics is beyond the scope of this review. These have
been reviewed previously (Weggen et al. 2007; Landreth
et al. 2008). Indomethacin, ibuprofen and diclofenac all act
as agonists for peroxisome proliferator-activated receptor-γ
(PPARγ). This nuclear receptor is a potent down-regulator
of NFκB activation and its targeting has had beneficial
effects in AD models (Lehmann et al. 1997; Combs et al.
2000; Landreth and Heneka 2001). Thus, the inhibition of
aspects of microglial function, such as IL-1β synthesis
(Heneka et al. 2005), seems more likely to occur via this
pathway than via prostaglandin inhibition. In addition, a
subset of NSAIDs including sulindac sulphide, ibuprofen
and indomethacin, but not including naproxen, aspirin or
selective COX-1 and COX-2 inhibitors SC-560 or cele-
coxib, lower Aβ1-42 independently of their impact on
COX activity (Weggen et al. 2001). This raised the
possibility that the effectiveness of NSAIDs in the
population may not be related to its effects on limiting
prostaglandin production. One recent study has examined
prostaglandins, cytokines, Aβ1-42 and cognitive effects in
a single study. Kotilinek et al. (2008) showed that
ibuprofen, naproxen and a tricyclic COX-2-specific drug
all restored memory function in Tg2576 mice and reversed
impairments of long-term potentiation (LTP) induced by
acute application of Aβ These effects were independent of
effects on Aβ42 and of effects on pro-inflammatory
cytokines. The authors reported that all effective drugs
shared a COX-2 inhibitory profile and that improved
memory function correlated with lower PGE2 levels.
However, both COX-2 mRNA and PGE2 levels were lower
in transgenics than in wild-type mice and were not affected
by the drug treatment. Thus while this study refocuses
attention on prostaglandins, the relationship between PGE2,
COX expression and memory dysfunction remains very
unclear.
Furthermore, the impact of NSAIDs in animal models of
AD has generally been assessed by long-term treatment
before any cognitive assessment. Therefore, the effect of
blocking inflammation and/or amyloidogenesis across a
number of weeks/months before cognitive testing has been
examined, and the ability of these drugs to lift the active
suppression of memory function by inflammatory media-
tors has not. In contrast, there is evidence for rapid reversal
of cognitive dysfunction when Aβ is directly targeted using
monoclonal antibodies in the Tg2576 (Kotilinek et al.
2002) or PDAPP (Dodart et al. 2002) strains. Collectively
these data suggest that some oligomeric species of Aβ is
directly impacting on memory in these mild cognitive
impairment or ‘prodromal’ models of AD and indeed there
is now good evidence for such direct impacts of Aβ
oligomers on hippocampal physiology (Walsh et al. 2002).
In contrast, the recent amyloid immunization clinical trial
demonstrates that even very successful removal of amyloid
plaques offers no relief to AD patients: all patients
followed-up after the AN1792 study died with terminal
dementia and an MMSE of zero (Holmes et al. 2008).
Therefore, NSAIDs and immunization effects in the animal
models may differ from their effects in AD patients and one
must make a comparison between the pathological aspects
in these models and those in the diseased patients who we
know are not protected by these drugs once impairments
are apparent (Fig. 2). Most animal models of AD show
limited neuronal and synaptic loss (Wirths and Bayer 2010)
and this is in sharp contrast to the devastating losses
incurred during AD progression: entorhinal cortex and
hippocampus show up to 50% pyramidal cell loss (Hyman
et al. 1984) and there are very significant losses of basal
forebraincholinergic(DaviesandMaloney1976;W h i t e h o u s e
et al. 1981, 1982) and locus coeruleus noradrenergic neurons
(Tomlinson et al. 1981). In addition, synaptic loss is very
marked and correlates better with cognitive dysfunction than
any other pathological feature including plaque burden
(Terry et al. 1991).
While animal models show that amyloid overproduction
can produce cognitive deficits, even the originators of the first
animal modelsofADnow suggest thatthese modelsprobably
represent a stage of disease that resembles mild cognitive
impairment (MCI) or perhaps even earlier (Ashe and Zahs
2010). Thus it is possible that NSAIDs in AD transgenics are
targeting a process that does not occur or has already passed
when these drugs are administered to patients with AD. This
timing issue could explain the discrepancy between benefi-
cial effects of NSAIDs in models and patients. There is
limited evidence that NSAIDs are beneficial at early stages
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initiated later in progression (Kukar et al. 2007). Therefore
the question arises: have animal models of AD demonstrated
that prostaglandins are not important in the evolution of
cognitive deficits, or have we failed to examine, in sufficient
detail, which enzymes synthesise which prostanoids in which
compartment at which time? In order to rationalise the
success or failure of these treatments in AD one also needs to
look in considerably more detail at the primary targets of
NSAIDs: COX isoforms.
Cyclooxygenases in disease and cognition
COXs are the essential and rate-limiting enzyme in the
synthesis of prostaglandins from arachidonic acid. PGG2 is
initially synthesized via the bis-oxygenase activity of COX,
followed by generation of PGH2 via the peroxidase
activity. This is then the starting point for a number of
other synthase enzymes to synthesize a wide spectrum of
prostanoids, the production of all of which would be
affected by COX inhibition (Fig. 3). It is now well
accepted, from epidemiological studies and meta-analyses
thereof, that inhibition of these enzymes with NSAIDs
significantly protects against the subsequent development
of AD (McGeer et al. 1996; In 'T Veld et al. 2001; Etminan
et al. 2003; Vlad et al. 2008). However, the resulting
clinical trials have consistently failed to demonstrate benefi-
cial effects in terms of treatment or prevention (Aisen et al.
2003; Lyketsos et al. 2007;M a r t i ne ta l . 2008). These
findings demand not just a better appreciation of the
temporal and neuroanatomical aspects of COX-1 and
COX-2 activation in disease but also of the normal roles of
these enzymes in memory and learning.
Two major isoforms of COX have been described,
COX-1 and COX-2, which appear to differentially affect
inflammation, blood flow, cell death and fever in the CNS
(Bosetti 2007). Both COX-1 and COX-2 are constitutively
expressed in the CNS; COX-1 is primarily expressed in
microglia and some neuronal populations (Yermakova et al.
1999; Hoozemans et al. 2001) and has recently been
shown in perivascular macrophages (PVMs) in rodents
(Garcia-Bueno et al. 2009). COX-2 is readily detected in
neurons in many brain regions, both in humans and in
rodents (Yasojima et al. 1999; Hoozemans et al. 2001).
Given that COX-2 is readily induced by inflammatory
stimuli in microglia and endothelium (Ek et al. 2001;
Uchikado et al. 2004), it has often been the pharmacolog-
ical target of choice against neuroinflammation. However,
the evidence that COX-2 increases as a function of
progression of AD is rather limited. It has been described
to be elevated at early stages of disease but later decreases
(Hoozemans et al. 2001). There are early reports of elevated
PGE2 in AD patients with respect to controls (Montine
et al. 1999), but one longitudinal study reported early
elevated PGE2 followed by declining levels as memory
declined (Combrinck et al. 2006). Importantly, higher
PGE2 levels also predicted longer survival. These data
may be consistent with an early inflammatory response, but
also suggest that there is an important role for COX-2
derived PGE2 in maintenance of memory function. There is
increasing evidence that constitutive, neuronal COX-2 func-
tion is essential for normal hippocampal function. Specific
inhibition of basal COX-2 activity was shown to inhibit
memory consolidation in Morris Water Maze experiments
(Teather et al. 2002) and later experiments repeated this and
showed that COX-1 inhibition did not impair memory
function (Cowley et al. 2008). Mechanistically, there is
evidence that PGE2, released from post-synaptic dendritic
spines can bind pre-synaptic prostaglandin receptors EP2
and/or EP4 and increase the amplitude of stimulus-evoked
excitatory post-synaptic potentials (EPSPs) in the hippocam-
pus (Sang et al. 2005). This facilitatory role of basal COX-2
derived prostaglandins is dependent on the activity of
cAMP-dependent protein kinase (Chen and Bazan 2005),
the primary signalling pathway induced by EP2 and EP4
receptor activation. Thus with respect to memory function
there are good reasons to believe that inhibition of COX-2
activity would be deleterious. Given these findings, the
Fig. 2 Key determinants of cognitive dysfunction. Evidence of the
contribution of different features of pathology to memory dysfunction in
AD.SuccessfulremovalofAβplaquesfailedtoimproveorhaltcognitive
declineinADpatients.Likewise,NSAIDtreatment,whilesuccessfulasa
long-term preventative strategy, was unsuccessful as a treatment for
establishedAD.Synapticlosscontributestocognitivedeclineandmay,to
some extent, be plastic/reversible. Neuronal loss is irreversible and its
progression will inevitably lead to cognitive decline. This suggests that
later stage cognitive decline in AD is likely to be chiefly caused by
synaptic and neuronal loss
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targeting COX-2 is rather surprising (Aisen et al. 2002,
2003; Reines et al. 2004; Lyketsos et al. 2007; Soininen et al.
2007; Aisen et al. 2008; Leoutsakos et al. 2011).
Conversely COX-1, while generally regarded as constitu-
tively active and notinducedby inflammation,isincreased in a
number of neurodegenerative diseases including AD
(Yermakova et al. 1999; Hoozemans et al. 2001)p r i o n
disease (Deininger et al. 2003) and HIV dementia (Griffin
et al. 1994). Furthermore the hypothesis that COX-1 is central
to mediating the neuroinflammatory response has been
gaining support in the literature (Choi et al. 2009).
Pharmacological inhibition or genetic deletion of COX-1
reduces LPS and β-amyloid-induced neuroinflammation
including reduced levels of NFκB-mediated pro-
inflammatory cytokine synthesis and decreased histological
evidence of microglial activation (Choi et al. 2008;C h o ia n d
Bosetti 2009). Recent cognitive studies show that in a model
chronic of CNS IL-1 over-expression that COX-1-generated
PGE2 produces deficits in contextual fear conditioning
(Matousek et al. 2010). With respect to CNS consequences
of systemic inflammation, it has been shown that COX-1-
selective inhibition protects against LPS-induced behavioural
depression while the COX-2 specific nimesulide does not
(Teeling et al. 2010). Our own recent work shows that
selective COX-1 inhibition can protect against LPS-induced
working memory deficits on a background of chronic
neurodegenerative disease (Skelly & Cunningham, unpub-
lished data) and there is emerging evidence that COX-1-
positive PVMs may be a key interface between systemic and
CNS inflammation (Garcia-Bueno et al. 2009). It is clear that
exogenously added or pathologically elevated PGE2 can
impair memory function in fear conditioning (Hein et al.
2007;M a t o u s e ke ta l . 2010) and runway tasks (Matsumoto et
al. 2004) and thus inhibition of COX-1 might be protective in
situations in which the levels of this enzyme and resulting
prostanoids have become elevated by pathology or acute
inflammatory stimulation. The important, but overlooked,
role of systemic inflammation in AD-related cognitive decline
is discussed below.
Inflammation exacerbates dementia: delirium
Despite the ongoing uncertainty about the role of inflam-
mation in cognitive dysfunction in dementia, it is absolutely
Fig. 3 Prostanoid synthesis and
action. The prostanoids originate
from the release of arachadonic
acid from membrane phospholi-
pids by phospholipase A2. AA
is subjected to bisoxygenase and
peroxidase activities of the
cyclooxygenases (or prostaglan-
dinG/Hsynthases) to form PGG2
and then PGH2. PGH2 is the
substrate for the synthases PGE2
synthase, PGD2 synthase, prosta-
cyclin synthase, PGF2a synthase
(PGF2a can also be synthesized
directly from PGE2) and
thromboxane synthase to
synthesize the individual classes
of prostanoids. These classes all
have discrete receptor subtypes
through which they initiate their
actions. The cyclooxygenases 1
and 2 are the primary targets of
NSAIDs but these may be
specific for one isoform or
another, selective, or non-
selective. Blocking the
production of PGH2 via COX
inhibition can reduce the levels
of all downstream prostanoids
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impairment in cases of delirium during dementia. Despite
the complete neglect of this area by basic researchers in
AD, understanding the mechanisms of this acute cognitive
impairment is likely to contribute to our understanding of
how inflammation alters cognition in clinical practice,
where patients with dementia frequently suffer co-
morbidities including systemic infections, injuries and
surgeries. Delirium is an acute and profound impairment
of consciousness and cognitive function (Burns et al. 2004;
Meagher 2009). It is well established that aging and
dementia are the major risk factors for episodes of delirium
(Fick et al. 2002) and systemic inflammatory episodes
are among the major triggers (MacLullich et al. 2008).
Significantly, the occurrence of delirium is known to
produce long-term cognitive impairments and to be
associated with more rapid progression of dementia
(Rockwood et al. 1999; Rahkonen et al. 2000;F o n ge ta l .
2009). Therefore, if systemic inflammation frequently
induces delirium in the demented population and this
accelerates dementia then identification of the inflammatory
mediators responsible for these episodes would be predicted
to be therapeutic targets also in dementia per se. However,
inhibition of such targets would not be predicted to offer
immediate relief in dementia, rather the positive effects
could only be appreciated across a relatively long period of
treatment during which the negative CNS consequences of
systemic inflammation would be blocked. This is consistent
with the efficacy of NSAIDs to protect against development
of dementia but their inability to treat established disease.
There is a growing body of evidence that systemic
inflammation (induced by LPS, poly I:C or chronic
systemic expression of IL-1β) can accelerate progression
and/or exacerbate features of pathology in a number of
animal models of neurodegenerative disease including
amyotrophic lateral sclerosis (Nguyen et al. 2004), prion
disease (Cunningham et al. 2005, 2009; Field et al. 2010),
3xTg-AD (Kitazawa et al. 2005), tau pathology (Lee et al.
2010), APP/PS1 (Sheng et al. 2003)a n dP a r k i n s o n ’s
Disease (Pott Godoy et al. 2008; Villaran et al. 2010).
Furthermore, that systemic inflammation accelerates cogni-
tive decline has also now been demonstrated in AD patients
(Holmes et al. 2009). Consistent with the idea of a
dementia/delirium continuum we have shown that repeated
systemic inflammatory challenges superimposed on ad-
vancing disease induce acute dysfunction followed by
recovery, but with each successive challenge the acute
exacerbation is more severe and less recoverable (Field
et al. 2010). It has been apparent for some time that
systemic LPS can alter amyloid processing (Brugg et al.
1995; Sly et al. 2001; Sheng et al. 2003; Lee et al. 2010),
but it is now clear that systemic inflammation, particularly
in the presence of microglia primed by prior pathology, can
induce a significant exacerbation of CNS inflammation,
causing de novo inflammatory damage. Such damage may
occur via iNOS, TNF-α, IL-1β, prostaglandins and many
other pathways (Fig. 4). These pathways merit considerably
more investigation in dementia but are beyond the scope of
this review and have recently been reviewed elsewhere
(Perry 2010; Cunningham 2011).
With respect to the delirious episode itself, there have
been a number of studies associating pro-inflammatory
cytokines with the occurrence of delirium after hip fracture
or hip replacement surgery and these studies have consis-
tently implicated IL-6, IL-8 and others (Beloosesky et al.
2007; van Munster et al. 2008, 2010; Maclullich et al.
2011). However, causation cannot be established in such
association studies. Thus, there is a need for animal model
studies of delirium. We have recently developed the first
animal model of delirium during dementia, employing the
superimposition of systemic LPS (100 μg/kg) on a
background of chronic progressive neurodegenerative dis-
ease, using the ME7 model of prion disease (Murray et al.
2010). These LPS challenges produce acute and reversible
working memory deficits in animals with prior chronic
neurodegenerative disease, but not in normal animals
challenged with LPS. This T-maze alternation working
memory deficit has good validity for clinical delirium since
the task is reliant on attention to the initially sampled arm
and short-term memory retention which are key features of
the delirious episode as defined by DSM IV and WHO
ICD-10 definitions (WHO 1992;A P A1994). In addition,
deficits are of acute onset and are transient, key diagnostic
criteria for delirium (Inouye et al. 1990).
There also exist somewhat similar studies in aging rodents.
Johnson and colleagues have shown working memory deficits
that consist of a reduced ability of LPS-treated aged animals to
learn the new location of a hidden platform which is moved
each day of testing, compared to aged or LPS-treated alone
(Chen et al. 2008). Barrientos et al. (2009), have shown in a
series of studies that infection with E. coli in aged animals
induces impairments of consolidation of new memories in
contextual fear conditioning experiments. These latter studies
implicated central IL-1β in this process (Frank et al. 2010).
The microglial priming hypothesis, whereby microglia are
primed by neurodegeneration (Cunningham et al. 2005)o r
aging (Godbout et al. 2005) to show an exaggerated CNS
IL-1β response to systemic inflammatory stimulation, has
been used to explain most of these findings on selective
memory deficits in neurodegeneration/aging (Fig. 4), although
this still requires further proof. In related studies on post-
operative cognitive dysfunction IL-1β and TNF-α have been
implicated in a failure to consolidate new memory for spatial
context following an inflammatory surgical insult (Cibelli
et al. 2010; Terrando et al. 2010). Using the T-maze task
described above, we have recently shown that the selective
66 J Neuroimmune Pharmacol (2012) 7:60–73COX-1 inhibitor piroxicam protects against this LPS-induced
working memory deficit in animals with neurodegeneration
while the COX-2-specific inhibitor nimesulide does not. The
latter is consistent with evidence that COX-2 inhibition
actually exacerbates the CNS consequences of systemic
inflammation (Blais et al. 2005) while the former is congruent
with our observation of up-regulation of COX-1 in both
microglia and PVMs during disease progression (Skelly &
Cunningham, unpublished data) and the recently described
role of COX-1-positive PVMs as transducers of systemic
inflammatory signals to the brain (Garcia-Bueno et al. 2009).
Thus, an amplification of the prostaglandin system in micro-
glia and PVMs may be a key facet of this susceptibility of
aging and/or neurodegeneratio n .I n h i b i t i o no fC O X - 1m a yb e
more attractive than inhibition of COX-2 for both physiolog-
ical and inflammatory reasons. It is striking that the COX-1
inhibition reported in our recent studies reduced PGE2 levels
but did not lead to any reduction of blood or brain IL-1β,
TNF-α, IL-6 or CXCL1 (mouse homolog of IL-8), all of
which were previously associated with delirium in clinical
studies. Levels of prostaglandins have never been measured in
studies of delirium and the role of the cyclooxygenase
pathway should be investigated in this population. Given the
wide array of prostanoids arising from COX activity (Fig. 3)
and the side effects that can be associated with COX inhibitors
it will be important to be as precise as possible about which
elements of these pathways one might want to inhibit. In this
light, further information on the prostanoid receptors involved
in this process will also be extremely important.
CNS physiological and pathological roles
of prostanoid receptors
PGE2signalsthroughtheEPreceptors1–4(Andreasson2010).
The discrete roles for different prostaglandin receptors are
currently an area of considerable research activity and a non-
exhaustive list of relevant studies have been summarised in
Table 1. Perhaps the most clearly defined role for any of the
EPs is EP3, which is responsible for temperature regulation
and in the generation fever (Ushikubi et al. 1998; Lazarus
et al. 2007) and it appears to be the most highly expressed
prostaglandin receptor in the brain (Sugimoto and Narumiya
2007). EP3 has also been hypothesized to be involved in acute
cognitive impairments via decreased BDNF transcription
(Hein and O'Banion 2009), but direct evidence that EP3 is
involved remains limited at this point.
Physiologically, EP1 receptors have an important role
in activation of the hypothalamic pituitary axis (HPA)
(Matsuoka et al. 2003) and have been shown to have a role
in dopamine signalling in the striatum (Matsuoka et al.
2005; Kitaoka et al. 2007). However, EP1 is also thought to
mediate neurotoxic effects in ischemia/excitotoxicity since
EP1 inhibition or deletion typically results in neuroprotec-
Fig. 4 The role of systemic inflammation in dementia and delirium.
Systemic inflammation can influence the progression of dementia and can
induce episodes of delirium. We propose that systemic inflammatory
mediators, including PGE2, can be released from endothelial, perivascular
and microglial cells to influence neuronal function acutely. In addition,
local microglial cells, primed by prior pathology, may secrete other
inflammatorymediatorsthatcontributetoneuronaldamageanddeath.The
pathways for acute dysfunction and those for damage and death may be
distinct from each other or may overlap significantly. The inflammatory
mediators shown are not intended to constitute an exhaustive list. PGE2:
prostaglandinE2,PVM:perivascularmacrophage,COX:cyclooxygenase,
EP1-4: prostaglandin receptors 1 to 4, NO: nitric oxide, IL-1β: interleukin
1β,T N F - α: tumor necrosis-α
J Neuroimmune Pharmacol (2012) 7:60–73 67tion via neuronal specific mechanisms such as improved
Ca
2+ homeostasis, (Kawano et al. 2006) and also vasocon-
striction (Ahmad et al. 2006a). It may be significant, in this
context, that vascular factors such as stroke disease, diabetes
mellitus, hypertension and hypotension increase the risk of
Alzheimer’s Disease (Breteler 2000; Kivipelto et al. 2001;
Vermeer et al. 2003; de la Torre 2004). These studies and
further evidence that COX-2 and downstream prostaglandin
receptors contribute to ischemic brain damage (Nogawa et al.
1997;I a d e c o l ae ta l . 2001; Kawano et al. 2006)s u g g e s ta n
important link between ongoing ischemic events, prostaglan-
dins and cognitive decline.
As discussed above, EP2 and possibly EP4 in hippo-
campal neurons have a role in synaptic plasticity whereby
post synaptic COX-2/mPGES1 make PGE2 which is
released during activity to act on presynaptic EP2/EP4 to
increase excitability (Sang et al. 2005). Consistent with this,
EP2 appears to be largely neuroprotective in stroke/
excitotoxicity (McCullough et al. 2004; Liu et al. 2005;
Ahmad et al. 2006b). However, there are a number of
studies suggesting that microglial EP2 contributes to
amyloid load and oxidative damage in the APP/PS1 model
(Liang et al. 2005), and both hampers microglial phagocy-
tosis and contributes to neurotoxicity (Shie et al. 2005).
Conversely, EP4 has recently been described to have an
anti-inflammatory role, limiting pro-inflammatory cytokine
synthesis induced by LPS (Shi et al. 2010). Although
pharmacological studies suggest that EP4 has a role in
cerebral vasoconstriction (Maubach et al. 2009) and in
promoting wakefulness (Huang et al. 2003), studies of EP4
function have been limited by the poor viability of EP4−/−
mice, suggesting a key developmental role in the cardiovas-
cular system (Nguyen et al. 1997).
There are, therefore, clear beneficial and deleterious
roles for most of the EP receptors and any aspiration to
inhibit the function of these receptors, particularly EP2, will
have to balance this inhibition with the important physio-
logical roles they serve. In addition to the 4 EP receptors,
there are also receptors for PGD2, PGI2, and PGF2a and
these have been very little studied in AD although it has
been shown that prostaglandin D synthase and the receptor
DP1 show increased expression in AD brains and in the
Tg2576 AD model (Mohri et al. 2007). Given that inhibition
of COX will reduce levels of all of these prostanoids,
characterization of these enzymes and receptors in AD is
also necessary.
The future of COX inhibition in AD
Despite the two decades that have passed since the discovery
that NSAIDs protect against subsequent development of AD,
the expressionandrolesofCOX-1, COX-2,PGsynthasesand
PG receptors in AD models and patients have still not been
adequately characterized. Given that NSAID clinical trials
typically inhibit an entire system of physiologically active
arachidonic acid metabolites, it is perhaps unsurprising that
the results have been confusing and sometimes contradictory.
Clinical trials with COX-2 inhibition have failed to show
benefitsand possiblyevenincreased conversiontoAD(Aisen
Table 1 CNS physiological and pathological roles of EP receptors
Receptor Putative functions References
EP1 Mediates LPS-induced HPA axis activation Matsuoka et al. 2003
Promotes dopaminergic signalling in the striatum Matsuoka et al. 2005; Kitaoka et al. 2007
Participates in control of impulsive behaviour Matsuoka et al. 2005; Kawano et al. 2006; Ahmad et al. 2006a
Contributes to neurotoxic effects following excitotoxic
insult and ischemic brain damage (via improved
Ca
2+ signaling and vasoconstriction)
EP2 Promotes synaptic plasticity via increases in the amplitude
of hippocampal stimulus-evoked EPSPs
Sang et al. 2005
Neuroprotective in models of stroke/excitotoxicity McCullough et al. 2004; Liu et al. 2005; Ahmad et al. 2006b
Contributes to amyloid load and oxidative damage in APP/PS1 Liang et al. 2005
Hampers phagocytosis and mediates neurotoxicity Shie et al. 2005
EP3 Mediates temperature response to PGE2, LPS and IL-1β Ushikubi et al. 1998; Lazarus et al. 2007
Mediates LPS-induced HPA axis activation; Matsuoka et al. 2003
EP4 Promotes synaptic plasticity via increases in the amplitude
of hippocampal stimulus-evoked EPSPs
Sang et al. 2005
Mediates cerebral vasoconstriction Maubach et al. 2009
Limits LPS-induced pro-inflammatory cytokine synthesis Shi et al. 2010
Mediates PGE2–induced wakefulness via activation
of the histaminergic system
Huang et al. 2003
68 J Neuroimmune Pharmacol (2012) 7:60–73et al. 2008) and one recent randomised placebo-controlled
clinical trial shows that the COX-1 selective inhibitor
Triflusal significantly reduces the rate of conversion
from amnestic mild cognitive impairment to dementia
(Gomez-Isla et al. 2008). The possibility that COX-1 is a
more appropriate target than COX-2 has not been given
sufficient consideration. The ADAPT trial reported that both
the non-selective inhibitor naproxen and the COX-2-specific
celecoxib failed to prevent the development of AD (Martin
et al. 2008). Follow up of these patients suggests that the
non-selective naproxen, but not celecoxib, is protective but
only if patients were cognitively normal at the outset of the
study and are observed for 3 years or more (Breitner et al.
2011). Further analysis suggests that naproxen may show
deleterious effects, while celecoxib may be protective, if
patients are already in a period of steep decline at the time of
treatment (Leoutsakos et al. 2011). Thus it seems plausible
that there is a long temporal window in which NSAIDs,
particularly non-selective or even COX-1 selective drugs, may
be effective in slowing AD development. However, these
drugs may become deleterious in later stages of disease, when
inflammation is more pronounced, cognitive reserve is more
diminished and inhibition of one or both COX isoforms may
interfere with crucial physiological functions. However, we do
not yet have the data to state this with confidence. The
emerging data on the negative impact of systemic inflamma-
tion on AD progression and the implication of COX-1, or
indeed cytokines such as IL-1β and TNF-α,i nt h i sp r o c e s s
requires considerably more investigation. Finally the eligibil-
ity criteria of future randomised AD clinical trials must be
carefully considered to ensure that we do not exclude patients
with co-morbid systemic inflammation, who might finally
demonstrate that interfering with inflammation during AD,
whether of systemic or central origin, can protect against
disease progression.
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